Connect Biopharma Holdings Ltd.(CNTB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNTB Connect Biopharma Holdings Ltd.

Post-Mkt 03-19 17:41:10 EDT

2.87

+0.15

+5.51%

盘后2.87

+0.000.00%

16:48 EDT

High3.00	Low2.78	Vol171.29K
Open2.85	D1 Closing2.72	Amplitude8.09%
Mkt Cap160.44M	Tradable Cap41.17M	Total Shares55.90M
T/O493.41K	T/O Rate1.19%	Tradable Shares14.34M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CNTB","market":"US","secType":"STK","nameCN":"Connect Biopharma Holdings Ltd.","latestPrice":2.87,"timestamp":1773950400000,"preClose":2.72,"halted":0,"volume":171293,"hourTrading":{"tag":"盘后","latestPrice":2.87,"preClose":2.87,"latestTime":"16:48 EDT","volume":198,"amount":568.26,"timestamp":1773953291508,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.055147058823529375,"floatShares":14344108,"shares":55903513,"eps":-0.888362,"marketStatus":"Post-Mkt","change":0.15,"latestTime":"03-19 17:41:10 EDT","open":2.85,"high":3,"low":2.78,"amount":493407.8249579,"amplitude":0.080882,"askPrice":2.95,"askSize":1000,"bidPrice":2.54,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.888362,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773964800000},"marketStatusCode":4,"adr":0,"adrRate":1,"listingDate":1616126400000,"exchange":"NASDAQ","adjPreClose":2.72,"postHourTrading":{"tag":"盘后","latestPrice":2.87,"preClose":2.87,"latestTime":"16:48 EDT","volume":198,"amount":568.26,"timestamp":1773953291508,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.973813,"impliedVol":1.5612,"impliedVolPercentile":0.761},"requestUrl":"/m/hq/s/CNTB/tweets","defaultTab":"tweets","newsList":[{"id":"2620262016","title":"Connect Biopharma Director James Huang Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620262016","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620262016?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:33","pubTimestamp":1773865995,"startTime":"0","endTime":"0","summary":"Connect Biopharma reported that director James Huang filed an initial statement of beneficial ownership. The filing reported indirect beneficial ownership of 12 million ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7ln6P5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"gpt_icon":0},{"id":"2620943844","title":"Connect Biopharma President David Leslie Szekeres files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620943844","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620943844?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:48","pubTimestamp":1773694098,"startTime":"0","endTime":"0","summary":"Connect Biopharma filed a Form 3 initial statement of beneficial ownership for David Leslie Szekeres, who is President. The filing reported 215,739 ordinary shares held directly. It also reported employee stock options covering 1.77 million ordinary shares with an exercise price of USD 1.77. The filing reported additional employee stock options covering 409,355 ordinary shares with an exercise price of USD 0.97.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL7w0zNk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2620494876","title":"Connect Biopharma CEO and Director Barry D Quart files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620494876","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620494876?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:47","pubTimestamp":1773694070,"startTime":"0","endTime":"0","summary":"Connect Biopharma reported that Barry Quart, its chief executive officer and a director, filed a Form 3 initial statement of beneficial ownership. Barry Quart reported direct ownership of 95,147 ordinary shares. He also reported indirect ownership of 128,887 ordinary shares through a joint account with his spouse. Barry Quart reported employee stock options covering 2.66 million ordinary shares with an exercise price of USD 1.77. He also reported employee stock options covering 700,000 ordinary shares with an exercise price of USD 2.69.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Ret","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL81qLJL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2620049482","title":"Connect Biopharma SVP of Finance Lisa Peraza files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620049482","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620049482?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:46","pubTimestamp":1773694005,"startTime":"0","endTime":"0","summary":"Lisa Peraza, Senior Vice President of Finance at Connect Biopharma, filed an initial statement of beneficial ownership. The filing reported 45,189 ordinary shares held directly. It also reported employee stock options covering 400,000 ordinary shares at an exercise price of USD 1.15. Additional options included 250,000 ordinary shares at an exercise price of USD 2.69.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL6VKMD9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"gpt_icon":0},{"id":"2620494844","title":"Connect Biopharma Director Kleanthis Gabriel Xanthopoulos Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620494844","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620494844?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:45","pubTimestamp":1773693901,"startTime":"0","endTime":"0","summary":"Connect Biopharma reported that director Kleanthis Gabriel Xanthopoulos filed an initial statement of beneficial ownership. The filing listed 80,000 ordinary shares held directly. It also reported stock options covering 89,220 ordinary shares with an exercise price of USD 8.16. The filing reported stock options covering 60,000 ordinary shares with an exercise price of USD 2.5.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL7lYdKP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"gpt_icon":0},{"id":"2620491021","title":"Connect Biopharma director Karen J. Wilson files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620491021","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620491021?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:43","pubTimestamp":1773693833,"startTime":"0","endTime":"0","summary":"Karen Wilson, a director at Connect Biopharma, filed an initial statement of beneficial ownership. The filing reported 10,000 ordinary shares held directly. It also reported stock options to buy 89,220 ordinary shares at USD 8.16 per share. Additional stock options covered 60,000 ordinary shares at USD 0.96 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDLbv5kQ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2620349102","title":"Connect Biopharma files Form 3 initial beneficial ownership statement for Director James A. Schoeneck","url":"https://stock-news.laohu8.com/highlight/detail?id=2620349102","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620349102?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:43","pubTimestamp":1773693799,"startTime":"0","endTime":"0","summary":"Connect Biopharma reported an initial statement of beneficial ownership for director James Schoeneck. James Schoeneck disclosed stock options to buy 120,000 ordinary shares at USD 2.38 per share. He also disclosed stock options to buy 60,000 ordinary shares at USD 2.5 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL6572lg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"gpt_icon":0},{"id":"2620491084","title":"Connect Biopharma Director Jean I Liu Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620491084","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620491084?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:41","pubTimestamp":1773693665,"startTime":"0","endTime":"0","summary":"Connect Biopharma reported an initial statement of beneficial ownership for director Jean Liu. Jean Liu beneficially owned stock options to buy 34,000 ordinary shares at a USD 22.29 exercise price. The filing also listed stock options for 60,000 ordinary shares at a USD 0.96 exercise price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL59pWv8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2618956524","title":"Connect Biopharma publishes corporate presentation on rademikibart IL-4Rα antibody development in asthma and COPD","url":"https://stock-news.laohu8.com/highlight/detail?id=2618956524","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618956524?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:54","pubTimestamp":1773150874,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDLb2N0Q5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"gpt_icon":0},{"id":"2618953684","title":"Connect Biopharma to present Phase 3 rademikibart atopic dermatitis data at AAD Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2618953684","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618953684?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:00","pubTimestamp":1773147655,"startTime":"0","endTime":"0","summary":"Connect Biopharma to present Phase 3 rademikibart atopic dermatitis data at AAD Annual Meeting               Connect Biopharma said results from Simcere’s Phase 3 RADIANT-AD study of rademikibart in m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDLbq8g2L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","CNTB","IE00B3QW5Z07.USD","NDAQ","SG9999014021.USD","IE00BKPKM429.USD","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","LU2210150020.SGD","LU2095319765.USD","BK4139","SG9999014039.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2618953540","title":"Results From Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to Be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (Aad) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2618953540","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618953540?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:00","pubTimestamp":1773147603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA7XCVQK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CNTB"],"gpt_icon":0},{"id":"2603690854","title":"BTIG Sticks to Its Buy Rating for Connect Biopharma Holdings (CNTB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603690854","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603690854?lang=en_us&edition=fundamental","pubTime":"2026-01-14 19:07","pubTimestamp":1768388855,"startTime":"0","endTime":"0","summary":"BTIG analyst Julian Harrison maintained a Buy rating on Connect Biopharma Holdings yesterday and set a price target of $10.00. The company’s shares...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-connect-biopharma-holdings-cntb-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-connect-biopharma-holdings-cntb-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTB"],"gpt_icon":0},{"id":"2603468099","title":"Lake Street Reaffirms Their Buy Rating on Connect Biopharma Holdings (CNTB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603468099","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603468099?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:16","pubTimestamp":1768313803,"startTime":"0","endTime":"0","summary":"In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Connect Biopharma Holdings, with a price target of $9.00. Fla...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-reaffirms-their-buy-rating-on-connect-biopharma-holdings-cntb-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-reaffirms-their-buy-rating-on-connect-biopharma-holdings-cntb-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTB"],"gpt_icon":0},{"id":"2602510267","title":"Connect Biopharma Holdings Ltd - Phase 1B Study Results for Rademikibart Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510267?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:15","pubTimestamp":1768223708,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CNTB"],"gpt_icon":0},{"id":"2602170765","title":"Connect Biopharma Announces New Data and Ongoing Trials for Rademikibart in Asthma and COPD","url":"https://stock-news.laohu8.com/highlight/detail?id=2602170765","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602170765?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222833,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings Ltd. has announced new data demonstrating a unique mechanism of action for rademikibart, supporting its best-in-class potential for the treatment of inflammatory diseases. The company is currently recruiting for a Phase 1b study of intravenously-administered rademikibart, with topline results expected in the first quarter of 2026. Recruitment is also ongoing for Phase 2 Seabreeze STAT studies targeting acute exacerbations in asthma and COPD, with topline data anticipated in mid-2026. Preliminary data from the ongoing Phase 1b study indicate increases in FEV1 occur significantly faster with intravenous administration compared to subcutaneous administration. Results from these studies will be presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL4Jt7sf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","SG9999014005.SGD","CNTB","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","BK4139","IE00B3QW5Z07.USD","BK4585","SG9999014021.USD","LU2210150020.SGD","SG9999014039.USD"],"gpt_icon":0},{"id":"2593544341","title":"Connect Biopharma Board Member Kan Chen Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2593544341","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593544341?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:32","pubTimestamp":1766525550,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings Ltd. announced that Kan Chen, Ph.D., a partner at Qiming Venture Partners, has resigned from its Board of Directors and the Nominating and Corporate Governance Committee, effective immediately. The resignation follows the company's recent shift to a more U.S.-centric strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL47CRmf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2588277472","title":"Connect Biopharma Initiated at Buy by Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2588277472","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588277472?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:10","pubTimestamp":1764609000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNTB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 01, 2025 12:10 ET (17:10 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"gpt_icon":0},{"id":"2585605524","title":"Connect Biopharma Holdings to Present at Evercore Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585605524","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585605524?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:00","pubTimestamp":1763992816,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings Ltd. will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:50 a.m. ET. The live webcast of the presentation will be accessible through the Investors section of the company's website, with an archived replay available for approximately 90 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL7ZYTkQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4585","BK4588","CNTB","BK4112","LU2095319765.USD","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","BK4139"],"gpt_icon":0},{"id":"2584009946","title":"Connect Biopharma Reports Significant Loss Amid Development Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2584009946","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584009946?lang=en_us&edition=fundamental","pubTime":"2025-11-18 12:07","pubTimestamp":1763438837,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings Ltd. ( ($CNTB) ) has released its Q3 earnings. Here is a breakdown of the information Connect Biopharma Holdings Ltd. pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/connect-biopharma-reports-significant-loss-amid-development-efforts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/connect-biopharma-reports-significant-loss-amid-development-efforts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2583563117","title":"Connect Biopharma Price Target Maintained With a $10.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2583563117","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583563117?lang=en_us&edition=fundamental","pubTime":"2025-11-13 18:05","pubTimestamp":1763028300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNTB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 05:05 ET (10:05 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.connectbiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0993},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.1826},{"period":"6month","weight":0.7325},{"period":"1year","weight":2.4098},{"period":"ytd","weight":-0.0355}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.028496},{"month":2,"riseRate":0.6,"avgChangeRate":-0.025044},{"month":3,"riseRate":0.4,"avgChangeRate":-0.054845},{"month":4,"riseRate":0.4,"avgChangeRate":-0.018116},{"month":5,"riseRate":0.6,"avgChangeRate":-0.072705},{"month":6,"riseRate":0.8,"avgChangeRate":0.091691},{"month":7,"riseRate":0.4,"avgChangeRate":0.150673},{"month":8,"riseRate":0.8,"avgChangeRate":0.204473},{"month":9,"riseRate":0.2,"avgChangeRate":-0.084295},{"month":10,"riseRate":0.4,"avgChangeRate":0.007717},{"month":11,"riseRate":0.2,"avgChangeRate":-0.108453},{"month":12,"riseRate":1,"avgChangeRate":0.142382}],"exchange":"NASDAQ","name":"Connect Biopharma Holdings Ltd.","nameEN":"Connect Biopharma Holdings Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Connect Biopharma Holdings Ltd.(CNTB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Connect Biopharma Holdings Ltd.(CNTB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Connect Biopharma Holdings Ltd.,CNTB,Connect Biopharma Holdings Ltd.股票,Connect Biopharma Holdings Ltd.股票老虎,Connect Biopharma Holdings Ltd.股票老虎国际,Connect Biopharma Holdings Ltd.行情,Connect Biopharma Holdings Ltd.股票行情,Connect Biopharma Holdings Ltd.股价,Connect Biopharma Holdings Ltd.股市,Connect Biopharma Holdings Ltd.股票价格,Connect Biopharma Holdings Ltd.股票交易,Connect Biopharma Holdings Ltd.股票购买,Connect Biopharma Holdings Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Connect Biopharma Holdings Ltd.(CNTB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Connect Biopharma Holdings Ltd.(CNTB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction